Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Celgene's collaboration works ever onward in solid tumors
Company: Celgene (CELG)
Therapy: LYC-55716, a RORgamma agonist licenses from Lycera Corporation
Disease: Solid tumors
News: Lycera announced that the phase 2a portion of their phase 1/2 ARGON study is set to begin enrolling. This study will seek to enroll 75 patients across six solid tumor cohorts, including non-small cell lung cancer, head and neck cancer, ovarian cancer, gastric/esophageal cancer, bladder cancer, and renal cancer. Top-line data presented at ESMO 2017 from the phase 1 portion of this study showed that 6 out of 11 patients achieved disease stabilization for at least 7 months.
